The COMPANION study seeks volunteers to test a software-based treatment for the symptoms of anxiety in those diagnosed with  Pulmonary Fibrosis (PF).

At home
study

Nine
weeks

Compensation
of $250

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Who can participate in this study?

You may be eligible if you meet the following criteria.

1. You have a diagnosis of any form of PF, and can provide a CT report (not images) confirming diagnosis

3. You have access to an internet-enabled smartphone or tablet

2. You have anxiety symptoms

4. You are NOT suffering from severe depression or thoughts of suicide/self-harm

Who can participate in this study?

You may be eligible if you meet both criteria.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

1.

You have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)

2.

You have some level of anxiety

How might at-home digital therapy help treat my anxiety related to PF?

Cognitive behavioral therapy (CBT) is a recommended first-line treatment for anxiety.  This digital therapy is available on any cell phone or tablet. In this study you may receive access to this treatment and provide your feedback on your experience with it over the next 9 weeks.

Click below to see if you are eligible.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

How can I participate?

STEP

01

Take a short survey  to check if you qualify for the study

STEP

02

If you pre-qualify, a member of our research team will reach out to schedule a video call to finalize your enrollment and get you set up to participate.

STEP

03

Once enrolled, you will be randomly placed into the therapy group or control group. Participate in daily 10 minute therapy sessions (therapy group) on your mobile device and questionnaires (all participants) over the course of 9 weeks.

What is this study about?

Receiving a diagnosis of pulmonary fibrosis (PF) is typically coupled with dyspnea, fatigue, and cough - symptoms that usually worsen. The impact of living with PF can have a negative effect on mental health.

Frequently asked questions

What is the purpose of this study?
This study will evaluate if cognitive behavioral therapy used on a smartphone or tablet device can reduce anxiety and increase wellbeing in patients with PF.
What will happen in this study?
If you decide to join this study, the study team will check if you are eligible for participation. They will check if you have an PF diagnosis and will also check if you fulfill the other criteria for participation in the trial. They will ask questions about the medicines you are using and if you have other diseases.

If you are eligible, you will be randomly placed into either the therapy group or control group. If you are part of the therapy group, you will receive the digital CBT on your smartphone or tablet, through which you will complete digital therapy sessions for approximately 10 minutes per day. There may also be activities suggested to you. If you are part of the control group, you will also be offered access to the digital therapy after you have completed the study. All parts of this study can be completed from home.

All participants will be asked to complete questionnaires via the Curebase online platform. Curebase is a US company running the study on behalf of Vicore. Everyone will receive the compensation.
What are the possible benefits of taking part?
By participating in this study, you may receive free access to a digital therapy. The control group will also be offered the digital therapy after completion. By using the digital therapy, you may experience a reduction in your anxiety. Information learned from the study may help people with PF managing their anxiety in the future.
What happens to the data provided?
Data will be pseudonymized and shared with Vicore to enable the continued development of the digital therapy. Your personal information will not be shared.
Who is organizing and funding the research?
Vicore pharma is a Swedish biotech company focused on therapies for patients with severe lung diseases.

If you have any further questions about this study, please reach out to almeestudy@curebase.com.